Medtronic Begins U.S. Clinical Trial of Recapturable Transcatheter Aortic Valve

Last week Medtronic, Inc. (NYSE: MDT) garnered the European CE Mark for its newest transcatheter aortic valve. Today the first U.S. patients received Medtronic's CoreValve Evolut R, launching a U.S. trial of 250 patients at 25 centers. This trial will look at safety and effectiveness of this device in patients at high or extreme risk for open-heart surgery.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news